Aptevo Therapeutics (APVO) Cash from Financing Activities (2015 - 2026)

Aptevo Therapeutics has reported Cash from Financing Activities for 12 years, with the latest figure at $871000.0 in Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $871000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.4 million (up 152.39% YoY) and the FY2025 annual result came in at $38.5 million, up 146.85% from the prior year.
• Cash from Financing Activities slipped to $871000.0 in Q1 2026 per APVO's latest filing, from $5.8 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $18.3 million in Q3 2025 and troughed at -$4.9 million in Q1 2022.
• A 5-year average of $3.6 million and a median of $3.5 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities sank 138.22% in 2022, then jumped 968.8% in 2023.
• Over 5 years, Cash from Financing Activities stood at $6.0 million in 2022, then plunged by 49.22% to $3.0 million in 2023, then surged by 120.62% to $6.7 million in 2024, then retreated by 13.78% to $5.8 million in 2025, then plunged by 84.97% to $871000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $871000.0, $5.8 million, and $18.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.